Skip to main content
. 2015 Jan 30;116:27–33. doi: 10.1016/j.antiviral.2015.01.009

Table 2.

Passive immunisation and AHSV challenge.

Groups Treatment Volume and VNAb titre of Serum Challenge AHSV-4
(a) Splenocyte transfer and challenge
Group 3 Transferred with splenocytes from Group 1b (MVA-VP2 vaccinates) 24 h before challenge 2 × 107 cells/mouse 106 pfu/mouse
Group 4 Transferred with splenocytes from Group 2 (MVA-wt vaccinates) 24 h before challenge 2 × 107 cells/mouse 106 pfu/mouse



(b) Serum transfer and challenge
Group 5 Transferred with serum from MVA-VP2 vaccinates (day 0) 1 h before challenge 400 μl S1a
2.25		 106 pfu/mouse
Group 6 Transferred with serum from MVA-VP2 vaccinates (day 0) 1 h before challenge 100 μl S1b
1.95		 106 pfu/mouse
Group 7 Transferred with serum from MVA-VP2 vaccinates (day −2) 48 h before challenge 100 μl S1b
1.95		 106 pfu/mouse
Group 8 Transferred with serum from MVA-VP2 vaccinates (day +2) 48 h after challenge 100 μl S1b
1.95		 106 pfu/mouse
Group 9 Vaccinated twice with MVA-wt 107 pfu per mouse 21 and 14 days before challenge N/A∗ 106 pfu/mouse
Group 10 Vaccinated twice with MVA-VP2 107 pfu per mouse 21 and 14 days before challenge N/A 106 pfu/mouse
*

N/A: not applicable.